KALV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
KalVista Pharmaceuticals Inc (KALV) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The strong analyst sentiment, positive technical indicators, and robust growth in product revenue support this recommendation, despite the pre-market price dip and some negative financial metrics.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 75.36, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 18.663 and R2: 19.65, with support at S1: 15.47. The overall trend suggests a positive price movement.
Strong analyst ratings with multiple price target increases (e.g., Stifel raised to $42, Citizens to $28).
Robust growth in Ekterly product revenue, with $49M in sales and strong refill metrics.
Expanding international market presence.
Bullish technical indicators.
Hedge funds are selling heavily, with a 7382.63% increase in selling last quarter.
Financial performance shows a significant drop in net income (-210.62% YoY) and EPS (-186.41% YoY).
Pre-market price is down by -0.95%.
In Q4 2025, revenue increased to $49.1M, driven by Ekterly's strong launch. However, net income dropped by -210.62% YoY, and EPS fell by -186.41% YoY. Gross margin remains high at 94.77%. The company has a strong cash position of $300.2M.
Analysts maintain a positive outlook with multiple Buy and Outperform ratings. Price targets range from $28 to $42, reflecting confidence in the company's growth trajectory and product success.
